Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
NEW YORK, Oct. 13, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM), a leader in the development of differentiat...
- ATNM-400 demonstrates robust efficacy in prostate cancer tumor models with acquired resistance to Pluvicto® and enzalutam...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $4 price ta...
- ATNM-400 shows; superior prostate cancer cell killing compared to androgen receptor inhibitor Xtandi® (enzalutamide), the ab...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $4 price ta...
- Initial clinical data expected in the second half of 2025 from this first-of-its-kind trial to administer a targeted ra...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $4 price ta...
- Results highlight ATNM-400's potential as a transformative therapeutic option for prostate cancer patients with unmet cl...
Actimab-A significantly potentiated and prolonged efficacy in combination with standard of care targeted therapies including hy...
